Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts

  Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos
  Assume New Posts

Business Wire

WASHINGTON -- April 11, 2014

Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the
Pharmaceutical Research and Manufacturers of America (PhRMA) today at the
trade association’s annual meeting. Also elected were Kenneth C. Frazier,
chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the
PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as
Board treasurer.

Mr. Read succeeds Robert J. Hugin, chairman and CEO of Celgene Corporation, as
PhRMA’s chairman.

“Bob Hugin is a true champion of the value that innovative medicines deliver
to patients, public health and our economy. Over the past year, his tireless
efforts to create new dialogues with partners in the patient community and
enthusiasm for better conveying the value of our sector have greatly enhanced
our advocacy for forward-looking policies that promote innovation and provide
patient access to new medicines,” said PhRMA President and CEO John J.

“At a time when collaborative medical science and healthcare delivery in the
U.S. and around the world are rapidly evolving, we are fortunate to have Ian
Read as chairman,” Castellani added. “His vision for the future of our
healthcare system will help guide PhRMA as we embark on the many challenges
and opportunities ahead.”

Mr. Read is the Chairman and CEO of Pfizer. He began his career with Pfizer in
1978 as an operational auditor. Mr. Read worked in Latin America through 1995,
in roles including Chief Financial Officer, Pfizer Mexico, and Country
Manager, Pfizer Brazil. In 1996, he was appointed president of Pfizer’s
International Pharmaceuticals Group, with responsibility for Latin America and
Canada. He became Executive Vice President, Europe, in 2000, and was named a
Corporate Vice President in 2001, assuming responsibility for Canada, in
addition to Europe, in 2002. Mr. Read later became accountable for operations
in both the Africa/Middle East region and Latin America. In 2006, he became
senior vice president, Pfizer, and Group President of the Worldwide
Biopharmaceutical Businesses, which he led through December 2010. In that
role, he oversaw five global business units — Primary Care, Specialty Care,
Oncology, Established Products and Emerging Markets.

“Our highest priority and purpose as an industry is to deliver life-saving
medicines to those who need them most. We are poised to enter another golden
era of innovation, transforming the way we do research and development to
speed the discovery of innovative new medicines,” Mr. Read said. “To be
successful in our purpose, we must have a reputation that ensures the full
support of all segments of civil society. We are judged, ultimately, by our
actions and we must work hard to earn the trust and respect of our regulators,
legislators, healthcare professionals, R&D partners and most importantly the
patients who depend on us, now and into the future.”

Mr. Frazier is chairman and CEO of Merck & Co. Previously he served as
president of Merck with responsibility for the company’s three major
divisions: Global Human Health, Merck’s sales and marketing division for
pharmaceutical and vaccine products; Merck Manufacturing, the company’s
manufacturing and supply division; and Merck Research Laboratories, Merck’s
research organization. Mr. Frazier held a broad range of senior management
positions since joining Merck in 1992 as vice president, general counsel and
secretary of the Astra Merck Group. He received his Bachelor’s degree from
Pennsylvania State University and holds a J.D. from Harvard Law School.

“The outstanding contributions being made to society by the biopharmaceutical
companies who make up PhRMA’s membership inspire me every day. I am
enthusiastic about my new responsibilities and look forward to supporting
PhRMA’s ongoing efforts to advance healthcare for patients, caregivers and
society,” Mr. Frazier said.

Dr. Scangos was appointed CEO of Biogen Idec in June 2010. He joined Biogen
Idec from Exelixis, Inc., where he served as president and CEO since October
1996. From 1987 to 1996, Dr. Scangos held various positions at Bayer, Inc.,
including SVP of R&D, and president of Bayer Biotechnology, where he was
responsible for research, business development, process development,
manufacturing, engineering and quality assurance of Bayer’s recombinant
products. Before joining Bayer in 1987, Dr. Scangos was Professor of Biology
at Johns Hopkins University. Dr. Scangos received a B.A. in Biology from
Cornell University, and a Ph.D. from the University of Massachusetts.

“We are entering an era of medical innovation that offers a real chance to
find therapies for some of the most challenging diseases, from Alzheimer’s, to
ALS, to many of the cancers that now have few or no treatments. Success will
require not only superior science but also sound public policy. I look forward
to working with my industry colleagues, policymakers, and others toward a
world where patients can reap the full promise of what our industry has to
offer,” said Dr. Scangos.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents
the country’s leading innovative biopharmaceutical research and biotechnology
companies, which are devoted to discovering and developing medicines that
enable patients to live longer, healthier, and more productive lives. Since
2000, PhRMA member companies have invested more than $550 billion in the
search for new treatments and cures, including an estimated $51.1 billion in
2013 alone.

Find PhRMA Online:

  *Website –
  *Facebook –
  *Blog –
  *Twitter – and
  *YouTube –

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health
emergencies, visit


Karl Uhlendorf, 202-835-3460
Press spacebar to pause and continue. Press esc to stop.